| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10219748 | Contraception | 2018 | 6 Pages |
Abstract
PAEC features may be explained by the altered genes and their networks affecting tissue architecture although not involved in endometrial cancer signaling pathways, and thus, treatment with mifepristone at this dosage does not show any adverse effect at endometrial level.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
C. Berger, N. Boggavarapu, E. Norlin, S. Queckbörner, K. Hörnaeus, A. Falk, M. Engman, M. Ramström, P.G.L. Lalitkumar, K. Gemzell-Danielsson,